.png)
Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial
Successful Full-Service, Randomized Pancreatic Cancer Phase II Trial Lead to a Unanimous Decision After SRC Data Review Meeting to Advance to Phase...
Current advances in RNA-based therapies hold substantial promise in treating and preventing many human diseases and disorders through curing the disease, rather than treating the symptomology like traditional therapeutics.
While many RNA therapeutics have made it to clinical trials, only a few have been approved. Veristat’s team of scientific-minded experts
have worked on over 60 RNA programs, including several approved
therapies. Our experience expands across the clinical development pathway in a broad range of therapeutic areas.
In this piece, learn how Veristat has supported some of our Biotech Sponsors in advancing their RNA therapeutics, including:
- A landmark RNA approval
- Navigating a full-service COVID-19 vaccine trial
- Ensuring a Successful Regulatory Agency Interaction
Meet Veristat. Learn More.
- Partner of Choice for Biologics
- Regulatory Considerations for Biosimilars Development in the US
- Marketing Application Support
- Full-Service Clinical Development Solutions
Strengthening Opportunities for Growth in the European Region
With the recent changes in clinical trial regulations and the growth of clinical trials in Europe, Veristat continues to build its footprint in the...
Regulatory TOPRA Webinar: Latest Regulatory Experiences
This year, our webinar centered on the challenges and opportunities associated with bringing novel medicinal products to market. No one in the...